To circumvent problems encountered in the synthesis of active chymosin in a number of bacteria and fungi, a recombinant DNA L-form expression system that directed the complete secretion of fully activable prochymosin into the extracellular culture medium was developed. The expression plasmid constructions involved the in-frame fusion of prochymosin cDNA minus codons 1 to 4 to streptococcal pyrogenic exotoxin type A gene (speA') sequences, including the speA promoter, ribosomal binding site, and signal sequence and five codons of mature SpeA. Secretion of fusion prochymosin enzymatically and immunologically indistinguishable from bovine prochymosin was achieved after transformation of two stable protoplast type L-form strains derived from Proteus mirabilis. The secreted proenzyme was converted by autocatalytic processing to chymosin showing milk-clotting activity. In controlled laboratory fermentation processes, a maximum specific rate of activable prochymosin synthesis of 0.57 x 10-3/h was determined from the time courses of biomass dry weight and product formation. Yields as high as 40 ± 10 ,ug/ml were obtained in the cell-free culture fluid of strain L99 carrying a naturally altered expression plasmid of increased segregational stability. The expressionsecretion system described may be generally useful for production of recombinant mammalian proteins synthesized intracellularly as aberrantly folded insoluble aggregates.
Chymosin, an aspartyl proteinase found in the abomasum of unweaned calves (7) , has been a prime target in many countries for production in genetically engineered microorganisms because of its indispensable role in cheese manufacturing and its limited availability. Notwithstanding tremendous efforts put into establishing chymosin-producing bacteria (2, 5, 14, (30) (31) (32) and fungi (3, 9, 27, 28, 34) , poor yields and aberrantly folded protein have been major obstacles to industrial utility. The stratagem commonly used for microbial expression of chymosin involves the linking of prochymosin cDNA (11, 29) to an appropriate host promoter and the 5' end of a structural gene to provide a ribosomal binding site together with an in-frame translation initiation codon. The synthesized prochymosin is then cleaved autocatalytically under acidic conditions to form the proteolytically active mature enzyme (6) . Expression systems designed for cytoplasmic prochymosin production invariably lead to insoluble protein aggregates which are largely unactivable. Therefore, exploiting secretion pathways favoring disulfide bond formation and correct protein folding appears to be mandatory for efficient microbial chymosin synthesis. However, for a variety of reasons, many of which are not well understood, there are limitations on the efficiency of prochymosin secretion by bacteria (Y. J. Vos, P. J. Lemson, A. L. M. Simonetti, and P. M. Andreoli, Abstr. Annu. Meet. Am. Soc. Microbiol. 1988, 0-5, p. 262) and fungi (34) .
Our strategy for microbial chymosin production involved both the construction of novel expression-secretion vectors and the use of cell wall-deficient bacteria as novel hosts. The expression unit we constructed is composed of prochymosin cDNA linked to the transcriptional, translational, and secretory control elements of the streptococcal pyrogenic exotoxin type A gene, speA (38) . The 10 ). Bacterial L forms have not served before as hosts for the production of recombinant proteins, but they promise to offer new assets, especially by secreting protein directly into the medium, owing to the absence of a periplasmic space. We describe here the quantitative release of recombinant prochymosin into the L-form culture medium and the conversion of this proenzyme to enzymatically active chymosin.
MATERIALS AND METHODS
Plasmids and bacterial strains. The plasmids used are described in Table 1 . Escherichia coli JM101 (39) or Streptococculs sanguiis Challis (obtained from Jon Ranhand) served as primary hosts for established and newly constructed plasmids. The strains LVI and L99 were stable protoplast type L forms derived by penicillin induction from P. mirabilis VI. They have been maintained in this institute by serial transfer in liquid antibiotic-free medium of normal osmolarity for more than 25 and 5 years, respectively. These organisms do not produce any organized constituents of the peptidoglycan layer and no longer revert to the parental bacterial form under any known conditions (10, 26, 35) .
Media and growth conditions. E. coli cells were grown aerobically in LB medium (21 (1) . Chymosin thus purified is called affinitypurified chymosin in this paper. Antiserum against affinitypurified chymosin was produced in rabbits by the intramuscular route as described by Louvard et al. (22) .
Transformation procedures. Transformation of competent E. coli cells with plasmid DNA was carried out by the calcium chloride procedure essentially as described by Dagert and Ehrlich (4) . For plasmid transformation of the P. mirabilis L-form strains, cells were grown in LFS medium with vigorous aeration for 18 h at 37°C. After centrifugation at 5,000 x g, the cell pellets were suspended in modified LFS medium containing 0.4 M sucrose to a density of about 1010 cells per ml. Samples (0.1 ml) of the cell suspensions were treated with 10 to 30 pL1 of plasmid DNA (300 p.g/ml) and 0.15 ml of 30% polyethylene glycol in 0.4 M sucrose. The mixtures were placed on ice for 10 min and incubated further for 10 min at 37°C with gentle shaking. After the addition of 0.9-ml volumes of modified LFS medium and incubation for an additional 3 h at 37°C, 0.1-ml samples were plated on LFS agar containing S pLg of erythromycin per ml. The plates were incubated for 5 to 10 days, after which the transformant colonies were transferred to fresh agar plates. Transformation frequency is expressed as the number of erythromycinresistant colonies per microgram of plasmid DNA. Growth in liquid medium was initiated with agar blocks overgrown with transformant cells, and serial passages in subcultures continued until adaptation to growth in liquid medium was attained.
DNA manipulation. Large-scale plasmid isolation was carried out by CsCl-ethidium bromide density gradient equilibrium centrifugation by the method of Maniatis et al. (25) . The method of Holmes and Quigley (12) 18 h at 37°C and read by comparing the sizes of the milk-clotting zones produced by the samples with those produced by a series of chymosin standard solutions made from affinitypurified calf chymosin.
RESULTS
Construction of prochymosin secretion vectors. The strategy used for the construction of prochymosin secretion vectors involved the in-frame insertion of the prochymosin cDNA downstream of the speA signal peptide processing site. Of the three starting plasmids characterized previously, pUC1833 (20) provided the speA promoter; pKMS3 (15) yielded the ribosomal binding site, the speA signal sequencecoding region, and the 5' end of prochymosin cDNA; and the complete remainder of the latter came from pKM9106 (15) . pUC1833 was cleaved with XbaI and PstI to yield the 3.4-kilobase (kb) recipient molecule for the insertion of the 0.3-kb XbaI-BgII fragment from pKMS3 and the 1.1-kb BglII-PstI fragment from pKM9106 (Fig. 1) . The three gel-purified fragments were joined in a directional cloning experiment to form pKM1836, containing the entire prochymosin expression-secretion cassette in the form of a 2.2-kb HindlIl fragment. In this construct, codons 1 to 35 came from speA, codons 36 to 38 were polylinker codons, and codons 39 to 399 corresponded to the complete prochymosin cDNA except for 15 nucleotides encoding the N-terminal pentapeptide (Fig. 1) . Since ampicillin resistance cannot serve as a selective marker in L forms, pKM1836 was fused with the streptococcal vector pSM6 encoding erythromycin resistance, as shown in Fig. 1 . Plasmid pSM6 (5.6 kb), which has a single EcoRI site, was derived previously from the group A streptococcal macrolide-lincosamide-streptogramin B resistance plasmid pSM10419 (22.4 kb) by a series of consecutive deletions which did not affect antibiotic resistance and replication functions (20) . A second plasmid selectable with erythromycin was obtained by inserting the 2.2-kb HindIII fragment from pKM1836 into pGK13 (Fig. 1) . The new constructs were transformed into E. coli JM101 with double selection for ampicillin plus erythromycin and chloramphenicol plus erythromycin, respectively, to yield clones carrying pKM636 (10.5 kb) or pKM1336 (7.1 kb) capable of replication and expressing erythromycin resistance in the P. mirabilis L-form strains.
Secretion of prochymosin and its activation to chymosin. The expression plasmids pKM636 and pKM1336 were transformed into P. mirabilis LVI was identified by Western blotting. Single positive bands were detected at identical positions for samples derived from strains carrying pKM1336 and pKM636 (Fig. 2) . The molecular weight of the reactive bands (Mr = 41,000) agreed with that deduced from the amino acid sequence of the expected fused protein without the 30-amino-acid signal sequence. As expected, authentic chymosin bands were detected at positions corresponding to an Mr of 36,000. Samples derived from isogenic strains lacking the prochymosin secretion cassette showed no immunologically reactive bands (Fig. 2) . Furthermore, the cytoplasmic protein fractions obtained by osmotic shock of cells carrying the expression plasmids were free of any detectable immunologically reactive materials.
In order to test the biological activity of the prochymosinreactive protein, cell-free culture fluids were examined after acidification and neutralization in well plates for milk-clotting activity by using authentic chymosin to calibrate the assay. Negative controls included samples derived from strains carrying plasmids free of the prochymosin expression cassette as well as unactivated samples from the producer strains. Representative results are illustrated in Fig. 3 . The minimum amount of purified commercial calf chymosin required to clot milk in the assay was about 3 ng per well. P. mirabilis L99 and LVI were each tested for prochymosin production with both pKM636 and pKM1336. (Fig. 4) . This result shows that the L-form cells synthesized and secreted prochymosin in an inactive form which was fully activable by a cleavage process which generated milk-clotting activity.
P. mirabilis L99(pKM636), which for unknown reasons produced significantly higher amounts of prochymosin than LVI for both expression plasmids, was used in fermentation processes to study the kinetics of prochymosin production during growth. When the fermentation started with an inoculum of 200 ml taken from 6-h shaken cultures, biomass dry weight production and prochymosin secretion were related until hour 16 (Fig. 5) . The maximum prochymosin yield (17.6 mg/liter) was obtained later than the maximum dry mass (4.2 g/liter), indicating the continuation of prochymosin synthesis in quasi-stationary-phase cells. Under the conditions of this experiment, the maximum specific rates of growth (0.183/h) and prochymosin synthesis (0.57 x 10-3/h) were obtained at hour 6 of fermentation, when the biomass doubling time was 1 2 kDa 67- 3.78 h and the pH value of the culture tended to increase above pH 7. To obtain stable prochymosin yields at the end of the fermentation process, we found it necessary to avoid pH values greater than 6.5 as soon as the biomass had ceased increasing, i.e., at hour 16 of fermentation. At no time in the course of fermentation was any intracellular prochymosin detectable, indicating, together with the immunological evidence mentioned above, that product secretion was virtually complete.
Deletion variant of pKM636 with increased stability and productivity. In the course of the initial posttransformation screening experiments designed to establish stable strains, a relatively high proportion of clones that harbored altered plasmids and exhibited highly variable chymosin production was observed. In a typical experiment, 41 erythromycinresistant and prochymosin-producing L99(pKM636) clones were isolated from the primary transformation plates and adapted to growth in liquid medium containing erythromycin. During the adaptation phase, eight clones lost the capability of producing activable prochymosin because of structural alterations of pKM636 which affected the prochymosin expression cassette, as evidenced by restriction analysis of their plasmids. The remaining 33 clones secreted prochymosin at levels ranging from 1 to 40 Vig/ml. Of these, the most productive clone was studied further. Its plasmid DNA was isolated and used to transform E. coli JM101 to ampicillin resistance. The ampicillin-resistant transformants were simultaneously erythromycin resistant but carried a deletion variant of pKM636 designated pKM6361 (6.8 kb). The deletion A6361 (indicated in Fig. 1) Cells adapted to growth in liquid medium containing erythromycin were washed and serially passaged at one-tenth the original density for 18 h at 37°C in shaken flasks containing antibiotic-free LFS medium. Saimples were differentially plated onto erythromycin-containing or antibiotic-free LFS agatr to determine the percentage of erythromycin-resistant colonies. The latter were simultaneously tested for prochymosin production and were always found to produce activable prochymosin in the milk-clotting assay. ' Ten serial passages corresponded to about 50 cell maiss doublings.
levels as high as 40 + 10 VLg/ml in adapted shaken cultures.
In addition, in the absence of erythromycin, pKM6361 proved to be more stably inherited than pKM636, from which it was derived ( Table 2) .
DISCUSSION
The results presented here show that biologically active chymosin can be produced in bacterial L forms. The identity of the protein was confirmed by demonstrating milk-clotting activity, reactivity with chymosin-specific antibodies in immunoblotting experiments, and processing of the proenzyme to a polypeptide having the molecular mass of authentic chymosin. The results imply that the transcriptional and translational control signals derived from a streptococcal gene (speA) to express prochymosin cDNA were functional in the heterologous host. Most importantly, since secretion is necessary for recombinant prochymosin to be activable, the present experimental design provided the first procaryotic system for chymosin production to enable the complete release of prochymosin into the extracellular culture medium. Although the precise signal sequence processing was not determined, the data obtained by SDS-polyacrylamide gel electrophoresis indicate that the 30-amino-acid SpeA signal peptide was processed. The hybrid preprochymosin encoded in the expression vector has a calculated molecular mass of 44.5 kilodaltons. Removal of the signal peptide would result in a polypeptide of 368 amino acids with an observed molecular mass of 41 kilodaltons. Of these, the seven N-terminal amino acid residues originated from speA' and the polylinker and replaced the N-terminal four amino acids of prochymosin. As shown before by others (2, 14, 27, 31) and confirmed here, the short N-terminal extension of foreign protein does not severely affect the autocatalytic processing activity of prochymosin. However, the autocatalytic activation rate might well be affected by the nature of the N-terminal extension, since the fused prochymosin expressed in P. inirabilis L forms required time periods for complete activation that were longer than those known to be necessary for the activation of authentic prochymosin (6) .
In engineering L forms to produce chymosin, we did not primarily aim at providing an alternative source of the enzyme for the cheesemaking industry. In view of the strict regulations concerning food additives, microorganisms more compatible with food processing may be more satisfactory, although they may pose their own problems. Rather, we developed the recombinant DNA L-form expression system VOL. 55, 1989 on June 16, 2017 by guest http://aem.asm.org/ Downloaded from as a possible alternative for the synthesis of mammalian gene products that, for one reason or another, have proved difficult to produce microbiologically. To assess the utility of the system, chymosin was chosen as a model because low product yields, incomplete secretion, aggregate formation, incorrect folding, breakdown by host proteases, and complexing with cell wall constituents are among the principal problems encountered in hitherto established microbial systems for its production. The L-form system compares favorably with these systems in any respect and may be advantageous for the production of other recombinant proteins synthesized intracellularly as insoluble aggregates. In the design of expression vectors to be used in L forms, ampicillin resistance is excluded as a selective marker. However, erythromycin resistance genes of the macrolide-lincosamidestreptogramin B resistance type from streptococci have proved to be perfectly suitable. As shown previously (23, 24) , these genes are well expressed in gram-negative bacteria, and furthermore, L forms are intrinsically much more sensitive to macrolides than are their normal bacterial forms (36) , enabling low concentrations of the antibiotics to be used for selection. Problems of plasmid stability remain and are presumably caused at least in part by the fundamentally altered cell surface structure and unequal cell division processes. However, structural alteration, if allowed to evolve under selective pressure and monitored so that it does not affect the desired functions, may rapidly lead to variants of the expression vectors that, as shown here for pKM6361, are more stably inherited.
